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A common polymorphism at codon 72 of exon 4
encoding either arginine or proline has been shown to
confer a susceptibility to the development of skin
tumor in renal transplant recipients. Moreover, this
polymorphism may affect proteolytic degradation of
p53 promoted by E6 protein from mucosal human
papillomaviruses and represent a risk factor for
human-papillomavirus-induced carcinogenesis. In this
study, we analyzed the human papillomavirus presence
and the TP53 allele distribution in cutaneous squamous
cell carcinoma of renal transplant recipients and
immunocompetent patients. Fifty-three squamous cell
carcinomas from 40 renal transplant recipients, 50
benign epithelial skin lesions from 50 renal transplant
recipients with no history of skin cancer, 51 squamous
cell carcinomas from immunocompetent patients, and
29 blood samples from immunocompetent individuals
without skin cancer were investigated. Human papillo-
mavirus DNA was detected using polymerase chain
reaction performed with two pairs of primers (MY09±
MY11 and FAP59±FAP64). TP53 allele distribution
was studied by denaturing gradient gel electrophoresis
assay, followed by sequencing analysis. Human papil-
lomavirus DNA was detected in 64% of squamous cell
carcinoma and 79% of benign epithelial lesions from
renal transplant recipients (NS) and only in 37% of
squamous cell carcinoma from immunocompetent
patients (p < 0.05). Mucosal oncogenic human papillo-
mavirus types were predominant in squamous cell car-
cinoma from both renal transplant recipients and
immunocompetent patients. Rate of arginine homo-
zygosity in squamous cell carcinoma from renal trans-
plant recipients was signi®cantly higher (83%) than in
immunocompetent patients with or without squamous
cell carcinoma (60% and 59%, respectively). Our
results suggest that TP53 arginine/arginine genotype
could represent a potential risk factor for the develop-
ment of squamous cell carcinoma in renal transplant
recipients compared to immunocompetent patients.
No association between TP53 arginine/arginine geno-
type and human papillomavirus status could be deter-
mined, however. Key words: human papillomavirus/p53
polymorphism/renal transplant recipient/squamous cell carci-
noma. J Invest Dermatol 118:1026±1031, 2002
R
enal transplant recipients (RTR) are at an increased
risk of developing nonmelanoma skin cancer and
the cumulative risk is 30%±60% 20 y after trans-
plantation, depending on geographic differences
and ethnic origin (Boyle et al, 1984; Blohme and
Larko, 1990; Hardie, 1995; Barba et al, 1996; LindeloÈf et al, 2000).
Squamous cell carcinomas (SCC) are the most prevalent, although
the frequency of basal cell carcinoma and malignant melanoma is
also increased. There are several speci®c factors that may explain
the susceptibility to skin cancer in RTR. The most important risk
factors are skin type, pretransplant and postransplant sun exposure
(Boyle et al, 1984), duration of immunosuppressive treatment
(Ducloux et al, 1998), immunogenetic factors linked to HLA class
II antigens (Bouwes Bavinck et al, 1997), and infection with human
papillomaviruses (HPV) (Bouwes Bavinck and Berkhout, 1997).
The high prevalence of HPV DNA detected in SCC from RTR
suggests a potential role for HPV infection in the etiology of these
tumors (Burk and Kadish, 1996). The types of HPV that are
possibly implicated are discussed as a wide diversity of HPV can be
detected within a single SCC, including mucosal HPV (types 6, 11,
16, and 18), epidermodysplasia verruciformis (EV) related subgroup
(types 5, 8, etc.), and other HPV types (Tieben et al, 1994;
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Shamanin et al, 1996; Hop¯ et al, 1997; de Jong-Tieben et al, 2000).
The carcinogenic effect of HPV may be explained in part by the
transforming viral protein E6, which binds to and induces the
degradation of p53 through the ubiquitin pathway (Scheffner et al,
1990), and inhibits apoptosis in response to ultraviolet irradiation
through other unexplained mechanisms (Jackson and Storey, 2000).
The equally high prevalence of EV-HPV infection in RTR with or
without a history of skin cancer (de Jong-Tieben et al, 2000),
however, suggests that, besides HPV infection, other factors may
play a critical role. Among them, genetic factors predisposing some
infected patients might account for different individual suscept-
ibilities in the development of skin cancer. A common poly-
morphism of the tumor suppressor gene TP53 that results in either
a proline (Pro) or arginine (Arg) at residue 72 of exon 4 has been
described (Matlashewski et al, 1987). The 72Arg form of the p53
protein appears to be particularly susceptible to HPV16, HPV18,
and HPV11 E6-associated degradation in vitro (Storey et al, 1998),
and could facilitate the oncogenic effect of HPV infection. In
addition, it has been demonstrated that the Arg-encoding allele may
represent a signi®cant risk factor in the development of SCC in
RTR (Storey et al, 1998). This ®nding was not con®rmed by a
recent report (Marshall et al, 2000b), however, and the importance
of TP53 polymorphism in HPV-associated tumors is still a matter of
controversy (Dokianakis et al, 2000; Bastiaens et al, 2001;
O'Connor et al, 2001). To gain insight into the role of genetic
variation of TP53 in skin carcinogenesis, we analyzed the HPV
presence and the TP53 allele distribution in cutaneous SCC and
benign epithelial lesions of RTR and immunocompetent patients
(ICP).
MATERIALS AND METHODS
Study population Only Caucasian French RTR or ICP were
included in the study to avoid confounding factors due to ethnic
differences, and informed consent was obtained. Fifty-three SCC from
40 different RTR, 50 benign cutaneous epithelial lesions (BCL) from 50
RTR, and 51 SCC from 51 ICP were included along with blood
samples from 29 healthy controls. The mean duration of
immunosuppression was similar in both groups of RTR (96 mo 6 69 vs
76 mo 6 60). All SCC from both RTR and ICP were located on sun-
exposed areas. As expected, the mean age at presentation of SCC was
signi®cantly lower in RTR (63 y) than in ICP (77 y), and the age of
patients with BCL was 46 y. We also tested blood samples from nine
RTR presenting SCC to analyze loss of heterozygosity (LOH).
DNA extraction Pathologic tissues (BCL and SCC) were ®xed either
with Bouin or buffered formalin, and embedded in paraf®n. Tumoral
cells were separated from normal surrounding tissues by microdissection.
Ten serial 5 mm paraf®n-embedded sections were used for DNA
extraction from these tissues as follows. Paraf®n was removed twice with
xylene (1 ml) and twice with absolute ethanol (1 ml). The pellet was air-
dried, resuspended in 100 ml of digestion buffer [50 mM Tris pH 8,
0.1 mM ethylenediamine tetraacetic acid (EDTA), 0.5% Tween-20,
200 ml per ml proteinase K], incubated overnight at 37°C, and then
boiled for 5 min. The DNA from blood samples was extracted using the
Quiagen kit as described by the manufacturer (Quiagen, France).
HPV genotyping After DNA extraction, the presence of HPV DNA
was tested by polymerase chain reaction (PCR) using two different sets
of L1 open reading frame consensus primers. MY09±MY11 primers
allowed the production of 450 bp amplicons and the detection of a
broad spectrum of mucosal HPV (Manos et al, 1989). The PCR
products were then typed using the Hybridowell kit, as we previously
described (Riethmuller et al, 1999). To genotype the most common
HPV, the amplimers were hybridized with internal 5¢ biotinylated probes
for low risk HPV 6, 11, or high risk HPV 16, 18, 31, 33, 35, 45, 51,
52, 58, 68. The primers FAP59±FAP64 generated amplicons of 480 bp
and ampli®ed not only a broad range of cutaneous HPV, including EV-
associated HPV types, but also mucosal HPV types (Forslund et al, 1999).
PCR of TP53 exon 4 and denaturing gradient gel electrophoresis
(DGGE) For DGGE analysis, TP53 exon 4 was ampli®ed with
consensus 40nGC-clamped primers TP53.4.1F±R that allowed the
production of a 224 bp fragment (Hildesheim et al, 1998). The primer
sequences were as follows: TP53.4.1F, 5¢-[40GC]CCTGGTCCTCTG-
ACTGCTCT-3¢; TP53.4.1R, 5¢-GTGTAGGAGCTGCTGGTGCA-3¢.
The ampli®cation was carried out in a 100 ml volume containing 1 3
PCR buffer (Perkin), 1.5 mM MgCl2, 200 mM of each dNTP, 2.5 U Taq
DNA polymerase (Ampli Taq, Perkin Elmer), 25 pmol of each primer,
and 1 mg of template DNA. After DNA denaturation, 35 cycles
consisting of 30 s at 94°C, 15 s at 60°C, 20 s at 72°C were performed,
followed by a 7 min ®nal extension at 72°C. The PCR products were
then analyzed by DGGE in the following conditions. A 16 3 18 cm,
1 mm thick, 8% acrylamide/Bis (37.5:1) gel with a parallel denaturing
gradient range of 35%±75% in 1 3 TAE buffer (40 mM Tris, 20 mM
acetic acid, 1 mM EDTA) was used. The gradient gel was cast using
Bio-Rad's Model 475 gradient delivery system. Forty microliters of PCR
products were mixed with 5 ml of 2 3 gel loading and electrophoresed
on the Dcode system. The gel was then stained with ethidium bromide
in 1 3 TAE buffer for 5 min and visualized under ultraviolet
transillumination. The DGGE analysis of 10 SCC from RTR, eight
SCC from ICP, and nine blood samples from RTR presenting SCC was
con®rmed by automatic sequencing, after puri®cation of their PCR
products (224 bp). Samples were subjected to cycle sequencing with the
forward primer TP53.4.1F without the 40nGC clamp using the CEQ
Dye Terminator Cycle Sequencing kit (Beckman Coulter) following the
cycling conditions: 20 s at 96°C, 20 s at 50°C, and 4 min at 60°C for 30
cycles ended by holding at 4°C.
Statistical analysis Pearson c2 test with Yates's correction when
necessary was carried out using Systat software to test the differences of
polymorphism according to virologic results. Statistical signi®cance was
considered at p < 0.05.
Table I. HPV types detected in SCC or BCL from RTR and ICP. Mucosal HPV were detected using MY09±MY11 PCR
primers and cutaneous HPV with FAP59±FAP64 PCR primers
% mucosal HPV % cutaneous HPV % coinfection Total
1- RTR + SCC (53) 58.5 (31) 24.5 (13) 19 (10) 64 (34)
2- RTR + BCL (38)a 66 (25) 26 (10) 13 (5) 79 (30)
3- ICP + SCC (51) 29 (15) 12 (6) 4 (2) 37 (19)
Statistical analysis
1 vs 2 NS NS NS NS
1 vs 3 p = 0.003 NS p = 0.017 p = 0.006
2 vs 3 p = 0.001 NS NS p = 0.001
a38 samples of 50 BCL were analyzed for HPV infection.
Table II. Frequency of mucosal HPV types detected in
SCC from RTR and ICP
HPV untyped 6/11 16 18 35 45 58 Total
RTR + SCC
(n = 31)
6.5
(2)
0
0
51.6
(16)
29
(9)
3.2
(1)
3.2
(1)
6.5
(2)
100
ICP + SCC
(n = 15)
0
0
0
0
66.6
(10)
26.7
(4)
0
0
0
0
6.7
(1)
100
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RESULTS
HPV status The overall prevalence of HPV is shown in
Table I.
Among BCL, 38 of 50 specimens were analyzed for HPV
infection, because b-globin DNA could not be ampli®ed in the
remaining specimens. Lack of b-globin DNA detection probably
resulted from disintegrated DNA probably linked to the Bouin
®xation procedure. HPV DNA was detected in 64% of SCC and
79% of BCL from RTR (p = 0.12), and only in 37% of SCC from
ICP (p = 0.006). In SCC from RTR, signi®cantly more mucosal
HPV were present (58.5%) than cutaneous HPV (24.5%) (p
= 0.001). Among mucosal HPV, HPV 16 and 18 predominated in
SCC of both RTR and ICP (Table II). In addition, coinfection
(mucosal and cutaneous HPV) was present in 10 SCC from RTR
(19%). It was notable that the ratio of positive cases for mucosal
HPV versus cutaneous HPV was similar in all groups of patients, i.e.,
2.4±2.5. This suggested that, although the prevalence of HPV
infection increased in RTR with SCC versus RTR with BCL versus
ICP with SCC, the ratio of mucosal HPV to cutaneous HPV
remained similar.
Genotypic distribution of TP53 gene Figure 1 shows the
representative results of DGGE analysis with three band shift
patterns. Single bands corresponded to homozygous p53 codon 72
genotypes, either Arg/Arg or Pro/Pro, whereas four bands attested
to a heterozygous genotype. After sequencing analysis of the single
bands, we con®rmed that the upper band corresponded to a Pro
genotype and the lower one to an Arg genotype (Fig 2).
Our test was validated on CaSki cells (Arg/Pro) and C33A cells
(Arg/Arg). Among SCC from RTR, 35 were genotyped and
compared to 35 SCC from ICP and 29 blood samples from healthy
controls. The polymorphism of TP53 was not studied in BCL
because of insuf®cient material. The proportions of p53 codon 72
genotype found were 83% Arg homozygous, 3% Pro homozygous,
and 14% Arg/Pro heterozygous in RTR with SCC, compared to
60% Arg homozygous, 9% Pro homozygous, and 31% Arg/Pro
heterozygous in ICP with SCC (Table III).
Statistical analysis showed that the homozygosity rate of Arg in
RTR with SCC was signi®cantly higher than in ICP with SCC (p
= 0.034). In addition, there were no signi®cant differences in the
distribution of the homozygous p53 Arg allele between ICP with
or without SCC (60% vs 59%). To verify the absence of LOH,
TP53 genotype at codon 72 was analyzed in nine SCC from RTR
and in nine blood samples from the same patients as described
previously. In all cases the TP53 genotype was similar both in the
SCC and in the blood sample, con®rming the absence of LOH.
Figure 2. Genotypic distribution of TP53 gene. Sequencing of p53 codon 72. The ®gure shows chromatograms from the CEQ2000 automat
sequencer. The letters above the peaks represent the appropriate base. The arrow indicates the codon 72 polymorphism. At the top, the sequence of
tumor DNA from RTR + SCC presenting a CGC (Arg) at codon 72 is shown. At the bottom, the sequence DNA from RTR + SCC presenting a
CCC (Pro) at codon 72 is shown.
Figure 1. Exon 4 DGGE analysis of TP53
gene in SCC. Lane 1: DNA from C33A cell
control homozygous Arg/Arg. Lane 2: DNA from
CaSki cell control heterozygous Arg/Pro. Lanes 3,
4, 6, 7, 8, 11, 12, 15: DNA from SCC samples
homozygous Arg/Arg. Lanes 9, 10, 13, 14, 16:
DNA from SCC samples heterozygous Arg/Pro.
Lane 5: DNA from SCC samples homozygous
Pro/Pro.
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Correlation between the presence of HPV and the p53
codon 72 Arg polymorphism The distribution of codon 72
TP53 genotype with respect to HPV status demonstrated similar
prevalences of Arg/Arg, Arg/Pro, and Pro/Pro in HPV-negative
samples and in HPV-infected patients. The statistical analysis did
not indicate any signi®cant association between HPV status and
TP53 polymorphism.
DISCUSSION
This study was conducted to compare the HPV status and TP53
codon 72 polymorphism in SCC and BCL from immunosup-
pressed RTR and in SCC from ICP. The blood samples of a
reference population of 29 healthy blood donors were used as
controls for TP53 codon 72 polymorphism.
With two pairs of HPV primers (MY09±MY11 and FAP59±
FAP64), we were able to detect a high rate of viral DNA in lesions
from RTR with no signi®cant differences in prevalence between
SCC and BCL (64% vs 79%) and between HPV types, either
mucosal (58.5% vs 66%) or cutaneous HPV (24.5 vs 26%). In SCC
lesions from ICP, the overall HPV presence was lower (p < 0.05).
In addition, mixed mucosal and cutaneous HPV types were mostly
detected in lesions from RTR, either SCC or BCL.
It was interesting to note that the ratio of positive cases for
mucosal HPV versus cutaneous HPV was similar in all groups. This
suggested that, although the prevalence of HPV infection increased
in RTR with SCC versus RTR with BCL versus ICP with SCC,
the ratio of mucosal HPV to cutaneous HPV remained similar. To
our knowledge this has never been previously noted. The different
studies on HPV infection in SCC from RTR are dif®cult to
compare, however, as different primers either for cutaneous HPV
or for mucosal HPV were used. In our study, the MY09±MY11
degenerate PCR system followed by typing with biotin-labeled
probes was successful in identifying, at a high rate, oncogenic
mucosal HPV types 16, 18. This is in agreement with the data
obtained by Euvrard et al (1993). Discrepancies with other studies,
which detected mostly EV or EV-related viruses (Berkhout et al,
1995), are likely to re¯ect the differing pro®les of the PCR primers
used. For identi®cation of cutaneous HPV, a general PCR method
using FAP59±FAP64 primers has recently been described (Forslund
et al, 1999). Such a method allows the detection of a large HPV
spectrum, including EV-related HPV, other HPV types (3, 10, 25,
27, 28, 29, 77, etc.), which are phylogenetically grouped with the
mucosal HPV types, and also low risk (6, 11, 42) or high risk (16,
18, 31, 52, 58, 68) mucosal HPV types. The involvement of
speci®c HPV types in promoting skin carcinogenesis cannot be
ruled out, as amplicons generated by that PCR have not been
sequenced in our study. The frequency of HPV DNA in lesions
(either benign or malignant) from ICP (37%) was signi®cantly
lower than in lesions from RTR (79% and 64%, respectively). It is
likely that immunosuppression may play a role in increasing
susceptibility to HPV infection in RTR. Other cofactors (i.e., sun
exposure or genetic variation) may also be involved in viral
replication, however.
It has been demonstrated that HPV alters TP53 stability. Indeed,
HPV E6 oncoprotein binds to p53 and induces its degradation
through the ubiquitin pathway (Scheffner et al, 1990). A recent
report (Storey et al, 1998) suggested that a common polymorphism
at codon 72 of the TP53 tumor suppressor gene might be a risk
factor in the development of HPV-associated cancers. The
previously suggested association between TP53 codon 72 Arg
homozygosity and SCC from RTR (Storey et al, 1998) is
con®rmed in our much larger study. Indeed, Storey et al (1998)
studied 32 HPV-infected SCC from 12 RTR and demonstrated a
striking excess of patients with only Arg (75%), rather than Arg/Pro
(25%) or Pro (0%) alleles. The relationship between TP53 status
and the presence of HPV in SCC was not established, and ICP with
and without SCC were not compared. In our study (Table III),
we analyzed 35 SCC from 40 RTR and found a strong prevalence
of Arg homozygosity (83%) compared to Arg/Pro heterozygosity
(14%) or Pro homozygosity (3%). In contrast, the rate of Arg
homozygosity in 35 SCC from ICP and in 29 leukocyte DNA
from healthy subjects was signi®cantly lower ± 60% and 59%,
respectively. Our data indicate that the TP53 codon 72 Arg allele
may confer susceptibility to the development of SCC after renal
transplantation. This contrasts with a previous study conducted
with a cohort of long-term survivors of renal transplantation
(Marshall et al, 2000b). The authors used leukocyte DNA for
detection of TP53 polymorphism and observed a 53% rate of Arg
homozygosity in 34 RTR with SCC, similar to rates of Arg
homozygosity in 188 RTR without SCC (53%) and in 84 controls
(46%).
When focusing on ICP with SCC or without SCC, our results
are in agreement with those obtained in previous studies (Hamel et
al, 2000; Bastiaens et al, 2001; O'Connor et al, 2001). The
distribution of the TP53 codon 72 genotype (Arg/Arg, Arg/Pro,
Pro/Pro) was similar in both groups: 60%, 32%, and 8% vs 59%,
24%, and 17%. Similar results were observed in recent reports
(Hamel et al, 2000; Bastiaens et al, 2001; O'Connor et al, 2001), and
the authors concluded that TP53 codon 72 Arg homozygosity does
not appear to represent a signi®cant risk factor for cutaneous SCC
in ICP. These results were not con®rmed by Dokianakis et al
(2000) in a study conducted on 29 high-risk HPV-related skin
lesions compared to blood samples from 61 healthy individuals.
The low rate of TP53 Arg/Arg (20%) in the control group,
however, compared with the frequency of TP53 codon 72 Arg
homozygosity (40%±80%) observed in most studies (Storey et al,
1998; Hamel et al, 2000; Marshall et al, 2000b; Bastiaens et al, 2001;
O'Connor et al, 2001) should be questioned. It has been proven
that p53 polymorphism varies according to geographic origin, and
the prevalence of TP53 Pro allele is closely related to latitude and
increases when approaching the Equator (Beckman et al, 1994). In
our study, we genotyped a well-established cohort of 40 RTR with
comparable immunosuppressive treatments. Although the lack of
information regarding skin type remains a possible confounding
variable, all individuals were of European Caucasoid origin (Eastern
France). Our study involves the ®rst French series of patients tested
for p53 polymorphism and gives new information on the
distribution of TP53 polymorphism in a homogeneous population.
Table III. Proportional distribution of TP53 genotype in SCC from RTR and ICP
% Arg/Arg % Arg/Pro % Pro/Pro
1- RTR + SCC (35)a 83 (29) 14 (5) 3 (1)
2- ICP + SCC (35)a 60 (21) 31 (11) 9 (3)
3- ICP (29 blood samples) 59 (17) 24 (7) 17 (5) (29 blood samples)
Statistical analysis
1 vs 2 p = 0.034
1 vs 3 p = 0.032
2 vs 3 NS
a35 patients of 40 RTR + SCC, 35 patients of 51 ICP + SCC, and 29 blood samples from ICP were analyzed for TP53 genotype.
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Another potential source of bias with previous studies (Storey et al,
1998; Dokianakis et al, 2000; Hamel et al, 2000; Marshall et al,
2000b; Bastiaens et al, 2001; O'Connor et al, 2001) is that
genotyping was not performed on similar material. For detection of
TP53 polymorphism, tumor material as well as leukocyte DNA can
be used. In our study, we evaluated TP53 polymorphism in skin
tumors from RTR and ICP, and in leukocyte DNA from ICP
without SCC. Storey et al (1998) performed TP53 genotyping on
DNA derived from SCC, whereas leukocyte DNA was used in
other studies (Dokianakis et al, 2000; Hamel et al, 2000; Marshall et
al, 2000b; Bastiaens et al, 2001; O'Connor et al, 2001). In addition,
the use of tumor material for detection of TP53 polymorphism may
be associated with the risk that LOH interferes with our results.
Indeed, LOH is frequently observed in skin cancer on chromosome
17p, where TP53 is located (Quin et al, 1994). Although Storey et
al (1998) demonstrated that LOH was not an important mechanism
for overrepresentation of TP53 Arg genotype in cervical HPV-
related cancer, at least two of the 12 RTR included in the same
study showed LOH in the SCC. Our study can potentially
eliminate such a bias, as we found the same genotype after testing
TP53 polymorphism on DNA from nine tumor specimens
compared to leukocyte DNA in the same patients.
Few studies determined the relation between HPV infection and
TP53 codon 72 polymorphism. We did not observe any association
between TP53 Arg/Arg genotype and HPV status as demonstrated
in two previous reports (Bastiaens et al, 2001; O'Connor et al,
2001). Storey et al (1998) and Dokianakis et al (2000) demonstrated
a high frequency of TP53 Arg homozygosity in HPV-associated
skin lesions, but no HPV-negative lesions or HPV-associated
controls were tested.
Altogether, our results indicate a signi®cant association between
TP53 codon 72 Arg homozygosity and cutaneous SCC in RTR,
but not in ICP with SCC. Thus, the TP53 codon 72 Arg allele
appears to be particularly important in immunosuppressed patients
who undergo cumulative effects of long-term immunosuppression
and increased susceptibility to HPV infection. Although the reason
is not clear, we may suggest that immunosuppression increases
susceptibility to HPV infection, particularly oncogenic mucosal
HPV types 16, 18, and 45 as we showed. Subsequently, HPV may
exert a carcinogenic effect by the transforming viral protein E6,
which induces the degradation of tumor suppressor protein p53
(Scheffner et al, 1990) and inhibits apoptosis in response to
ultraviolet radiation (Jackson and Storey, 2000). Thus, the cumu-
lative effect of immunosuppression, oncogenic HPV infection, and
TP53 codon 72 Arg homozygosity may explain the increased
prevalence of HPV-infected SCC in RTR patients. There is also
evidence against HPV E6 having a pathogenic role with respect to
p53 inactivation in SCC (McGregor et al, 1997), however, as
ultraviolet-related TP53 mutations are implicated in post-transplant
skin cancer irrespective of HPV status. In addition, Marin et al
(2000) showed that a common TP53 polymorphism at codon 72 of
exon 4 in¯uences the ability of certain p53 mutants to form stable
complexes with p73 protein. Formation of such complexes
correlates with a loss of p73 DNA-binding capability, and
consequently its ability to serve as a sequence-speci®c transcrip-
tional activator of TP53 and an inducer of apoptosis. The authors
demonstrated that the ability of mutant p53 to bind p73, neutralize
p73-induced apoptosis, and transform cells was enhanced when
codon 72 of TP53 gene encoded Arg. In addition, the Arg-
containing allele was always preferentially mutated in nonmelano-
ma skin cancer and all p53 mutants bound to p73. These data
suggest that codon 72 plays a major role in skin carcinogenesis
irrespective of HPV infection. Other studies, however, have shown
that p73 may be inactivated by both high- and low-risk HPV E6,
independently of ubiquitin-mediated proteolysis (Park et al, 2001),
and that expression of p73 is driven by E2F-1 (Irwin et al, 2000;
Lissy et al, 2000). Furthermore, O'Nions et al (2001) have suggested
that E7 proteins in HPV-positive tumors may be associated with
pRb and deregulate expression of E2F-1 and correspondingly p73.
These observations strongly suggest that p53 homolog p73 may also
have a role in skin carcinogenesis, and that interaction between this
homolog and HPV may be relevant. Its role in immunocompro-
mised patients remains to be elucidated, however. Moreover,
intratype variation in the E6 gene of HPV 16 has been recently
suggested as a possible additional factor in determining the
susceptibility to cervical cancer associated with the TP53 Arg
isoform (van Duin et al, 2000). As our data showed that oncogenic
mucosal HPV types 16, 18, and 45 predominated in SCC of RTR,
we may suggest that an association of TP53 codon 72 Arg/Arg
genotype and infection by such viruses may confer a high risk of
SCC development in RTR (Table IV). In addition, other
cofactors such as ultraviolet radiation and related genetic variations
(Marshall et al, 2000a) and other transforming or mutagenic
properties of E6 or other viral proteins (Jackson and Storey, 2000)
should be investigated in these patients as well as in ICP.
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